775 related articles for article (PubMed ID: 21751200)
1. Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas.
von Mehren M; Rankin C; Goldblum JR; Demetri GD; Bramwell V; Ryan CW; Borden E
Cancer; 2012 Feb; 118(3):770-6. PubMed ID: 21751200
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.
Maki RG; D'Adamo DR; Keohan ML; Saulle M; Schuetze SM; Undevia SD; Livingston MB; Cooney MM; Hensley ML; Mita MM; Takimoto CH; Kraft AS; Elias AD; Brockstein B; Blachère NE; Edgar MA; Schwartz LH; Qin LX; Antonescu CR; Schwartz GK
J Clin Oncol; 2009 Jul; 27(19):3133-40. PubMed ID: 19451436
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO).
Ray-Coquard I; Italiano A; Bompas E; Le Cesne A; Robin YM; Chevreau C; Bay JO; Bousquet G; Piperno-Neumann S; Isambert N; Lemaitre L; Fournier C; Gauthier E; Collard O; Cupissol D; Clisant S; Blay JY; Penel N;
Oncologist; 2012; 17(2):260-6. PubMed ID: 22285963
[TBL] [Abstract][Full Text] [Related]
4. Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948).
Raut CP; Boucher Y; Duda DG; Morgan JA; Quek R; Ancukiewicz M; Lahdenranta J; Eder JP; Demetri GD; Jain RK
PLoS One; 2012; 7(2):e26331. PubMed ID: 22347360
[TBL] [Abstract][Full Text] [Related]
5. Phase II prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapy.
Santoro A; Comandone A; Basso U; Soto Parra H; De Sanctis R; Stroppa E; Marcon I; Giordano L; Lutman FR; Boglione A; Bertuzzi A
Ann Oncol; 2013 Apr; 24(4):1093-8. PubMed ID: 23230134
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.
De Sanctis R; Marrari A; Marchetti S; Mussi C; Balzarini L; Lutman FR; Daolio P; Bastoni S; Bertuzzi AF; Quagliuolo V; Santoro A
Drug Des Devel Ther; 2015; 9():5785-91. PubMed ID: 26604682
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial.
Pacey S; Ratain MJ; Flaherty KT; Kaye SB; Cupit L; Rowinsky EK; Xia C; O'Dwyer PJ; Judson IR
Invest New Drugs; 2011 Jun; 29(3):481-8. PubMed ID: 20016927
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of sorafenib in advanced thyroid cancer.
Gupta-Abramson V; Troxel AB; Nellore A; Puttaswamy K; Redlinger M; Ransone K; Mandel SJ; Flaherty KT; Loevner LA; O'Dwyer PJ; Brose MS
J Clin Oncol; 2008 Oct; 26(29):4714-9. PubMed ID: 18541894
[TBL] [Abstract][Full Text] [Related]
9. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment.
Strumberg D
Drugs Today (Barc); 2005 Dec; 41(12):773-84. PubMed ID: 16474853
[TBL] [Abstract][Full Text] [Related]
10. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial.
Matei D; Sill MW; Lankes HA; DeGeest K; Bristow RE; Mutch D; Yamada SD; Cohn D; Calvert V; Farley J; Petricoin EF; Birrer MJ
J Clin Oncol; 2011 Jan; 29(1):69-75. PubMed ID: 21098323
[TBL] [Abstract][Full Text] [Related]
11. Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420.
Williamson SK; Moon J; Huang CH; Guaglianone PP; LeBlanc M; Wolf GT; Urba SG
J Clin Oncol; 2010 Jul; 28(20):3330-5. PubMed ID: 20498388
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.
Mir O; Brodowicz T; Italiano A; Wallet J; Blay JY; Bertucci F; Chevreau C; Piperno-Neumann S; Bompas E; Salas S; Perrin C; Delcambre C; Liegl-Atzwanger B; Toulmonde M; Dumont S; Ray-Coquard I; Clisant S; Taieb S; Guillemet C; Rios M; Collard O; Bozec L; Cupissol D; Saada-Bouzid E; Lemaignan C; Eisterer W; Isambert N; Chaigneau L; Cesne AL; Penel N
Lancet Oncol; 2016 Dec; 17(12):1732-1742. PubMed ID: 27751846
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307.
Dubey S; Jänne PA; Krug L; Pang H; Wang X; Heinze R; Watt C; Crawford J; Kratzke R; Vokes E; Kindler HL
J Thorac Oncol; 2010 Oct; 5(10):1655-61. PubMed ID: 20736856
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.
Abou-Alfa GK; Johnson P; Knox JJ; Capanu M; Davidenko I; Lacava J; Leung T; Gansukh B; Saltz LB
JAMA; 2010 Nov; 304(19):2154-60. PubMed ID: 21081728
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib.
Kelly RJ; Rajan A; Force J; Lopez-Chavez A; Keen C; Cao L; Yu Y; Choyke P; Turkbey B; Raffeld M; Xi L; Steinberg SM; Wright JJ; Kummar S; Gutierrez M; Giaccone G
Clin Cancer Res; 2011 Mar; 17(5):1190-9. PubMed ID: 21224376
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia.
Nimeiri HS; Oza AM; Morgan RJ; Huo D; Elit L; Knost JA; Wade JL; Agamah E; Vokes EE; Fleming GF
Gynecol Oncol; 2010 Apr; 117(1):37-40. PubMed ID: 20117828
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Cheng AL; Kang YK; Chen Z; Tsao CJ; Qin S; Kim JS; Luo R; Feng J; Ye S; Yang TS; Xu J; Sun Y; Liang H; Liu J; Wang J; Tak WY; Pan H; Burock K; Zou J; Voliotis D; Guan Z
Lancet Oncol; 2009 Jan; 10(1):25-34. PubMed ID: 19095497
[TBL] [Abstract][Full Text] [Related]
18. Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer.
Aragon-Ching JB; Jain L; Gulley JL; Arlen PM; Wright JJ; Steinberg SM; Draper D; Venitz J; Jones E; Chen CC; Figg WD; Dahut WL
BJU Int; 2009 Jun; 103(12):1636-40. PubMed ID: 19154507
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma.
Mahmood ST; Agresta S; Vigil CE; Zhao X; Han G; D'Amato G; Calitri CE; Dean M; Garrett C; Schell MJ; Antonia S; Chiappori A
Int J Cancer; 2011 Oct; 129(8):1963-9. PubMed ID: 21154746
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of sorafenib in patients with refractory or relapsed acute leukemias.
Borthakur G; Kantarjian H; Ravandi F; Zhang W; Konopleva M; Wright JJ; Faderl S; Verstovsek S; Mathews S; Andreeff M; Cortes JE
Haematologica; 2011 Jan; 96(1):62-8. PubMed ID: 20952518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
